UBS raised the firm’s price target on Carter’s (CRI) to $33 from $26 and keeps a Neutral rating on the shares. Carter’s reported better than expected Q3 results, but the report likely isn’t a positive for the stock, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRI:
- Carter’s Announces $500M Senior Notes Offering
- Carter’s price target raised to $25 from $22 at Wells Fargo
- Carter’s price target raised to $34 from $28 at Citi
- Carter’s price target raised to $26 from $23 at Barclays
- Carter’s Inc. Faces Risks and Challenges in Restructuring Efforts: Potential Impacts on Profitability